Serotonin syndrome: SSRIs, SNRIs, triptans, and current clinical practice

Headache

Volumn 52, Issue 2, 2012, Pages 195-197

  Tepper, Stewart J ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CYPROHEPTADINE; DIPHENHYDRAMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIPTAN DERIVATIVE;

ANXIETY; CLINICAL PRACTICE; COMORBIDITY; DEATH; DEPRESSION; ELECTRONIC MEDICAL RECORD; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; HUMAN; HYPERTHERMIA; MIGRAINE; MONOTHERAPY; MOOD DISORDER; MORBIDITY; NEUROLOGIST; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME;

FEMALE; HUMANS; MALE; RISK; SEROTONIN RECEPTOR AGONISTS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; TRYPTAMINES;

EID: 84857046115     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.02076.x     Document Type: Review

References (12)

1. Sternbach H,. The serotonin syndrome. Am J Psychiatry. 1991; 148: 705-713.
2. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM,. The Hunter serotonin toxicity criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003; 96: 635-642. (Pubitemid 37063272)
3. Food and Drug Administration. Information for healthcare professionals: Selective serotonin reuptake inhibitors (SSRIs), selective serotonin- norepinephrine reuptake inhibitors (SNRIs), 5-hydroxytryptamine receptor agonists (triptans). July 19, 2006. [Accessed December 21, 2011]. Available from http://www.fda.gov/cder/drug/InfoSheets/HCP/triptansHCP.htm
4. Evans RW,. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: An analysis of the 29 case reports. MedGenMed. 2007; 9: 48. [Accessed August 1, 2008]. Available from.
5. Soldin OP, Tonning JM,. Serotonin syndrome associated with triptan monotherapy. N Engl J Med. 2008; 358: 2185-2186. (Pubitemid 351679628)
6. Evans RW,. More on serotonin syndrome associated with triptan monotherapy. N Engl J Med. 2008; 359: 1533-4406.
7. Gillman PK,. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): A review. Headache. 2010; 50: 264-272.
8. Sclar DA, Robison LM, Castillo LV, et al,. Concomitant use of a triptan and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. Headache. 2012; 52.
9. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S,. Coprescriptions of triptans with potential interacting medications: A cohort study involving 240,268 patients. Headache. 2003; 43: 44-48. (Pubitemid 36150989)
10. Shapiro RE, Tepper S,. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007; 47: 266-269.
11. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE,. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society Position Paper. Headache. 2010; 50: 1089-1099.
12. Mackay FJ, Dunn NR, Mann RD,. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999; 49: 871-874. (Pubitemid 29504898)